[Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children].
Zhongguo Dang Dai Er Ke Za Zhi
; 17(8): 819-24, 2015 Aug.
Article
in Zh
| MEDLINE
| ID: mdl-26287346
ABSTRACT
OBJECTIVE:
To study the efficacy and safety of Chinese Childhood Leukemia Group ALL 2008 (CCLG-ALL2008) protocol combined with tyrosine kinase inhibitor (TKI, imatinib) for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in children.METHODS:
The clinical data of 53 patients aged less than 15 years when first diagnosed with Ph+ ALL between October 2008 and December 2013 were retrospectively analyzed. The patients were assigned to two groups HR (n=26) and HR+TKI (n=27). The HR group was treated with CCLG-ALL2008 protocol (for high-risk patients). The HR+TKI group was treated with imatinib in combination with CCLG-ALL2008 protocol (for high-risk patients).RESULTS:
The complete remission rate and chemotherapy induction-related mortality rate in the TKI+HR and HR groups were 100% vs 75% and 0 vs 15%, respectively. The 3-year event-free survival (EFS) rate in the HR group was (6±5)%; the 5-year EFS rate of the TKI+HR group was (52±11)%. Compared with the HR group, the TKI+HR group had no increase in the toxic responses to chemotherapy and had a decrease in the infection rate during the induction period.CONCLUSIONS:
Application of imatinib significantly improves the clinical efficacy in children with Ph+ ALL and has good safety.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Protein Kinase Inhibitors
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/
Imatinib Mesylate
/
Antineoplastic Agents
Type of study:
Guideline
Limits:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Language:
Zh
Journal:
Zhongguo Dang Dai Er Ke Za Zhi
Year:
2015
Type:
Article
Affiliation country:
China